[Expression of XXXX and analysis of prognostic factors in primitive neuroectodermal tumor].

@entity1 @entity6196 @entity15735 @entity5 @entity3778 @entity3508 @entity2277 @entity21468
OBJECTIVE: To observe the expression of @entity21468 in @entity6196 ( @entity6196 ), explore the value of immunohistochemical staining of @entity21468 in combination with other neural markers in diagnosis of @entity6196 , and analyze the prognostic factors in @entity6196 @entity1 . METHODS: 35 cases of @entity6196 , of which 33 cases with complete clinical data, were included in this study. Immmunohistochemistry (The En Vision method) was applied to detect the expression of @entity21468 , @entity3778 , @entity15735 , @entity3508 , S-100, NF, @entity2277 in the @entity5 tissues. The clinicopathological data of 33 cases were analyzed by Cox regression. RESULTS: The positive expression rate of @entity21468 were 51.4% and that of @entity3778 was 88.6%. The sensitivity of @entity21468 combined with @entity3778 was up to 100%. The positive rates of @entity2277 , @entity15735 , @entity3508 , s-100 and NF were 91.4%, 48.6%, 45.7%, 22.9% and 0, respectively. Cox regression analysis showed that the impact of primary location and treatment modality were of statistical significance (P < 0.05), but the age, sex, stage or size of @entity5 did not (P > 0.05). CONCLUSION: Immunohistochemical detection of @entity21468 and neural markers is a preferred method for clinical diagnosis of @entity6196 . The main factors affecting the prognosis are the primary location of @entity6196 and treatment modality.
